Selected research
Industry Research
Gefitinib Industry Research Report 2026
Market perspective
The global Gefitinib market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Gefitinib is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Gefitinib is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Gefitinib is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Gefitinib include Qilu Pharmaceutical, AstraZeneca, Zuventus Healthcare, United Biotech, Sichuan Xieli Pharmaceutical, Panacea Biotec, Nobel Ilac Sanayii Ve Ticaret, Nishchay Pharmaceuticals and Natco Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Gefitinib market in terms of revenue (US$ million) and, where applicable, sales volume (k pcs), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k pcs) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Gefitinib Market by Company
Qilu Pharmaceutical
AstraZeneca
Zuventus Healthcare
United Biotech
Sichuan Xieli Pharmaceutical
Panacea Biotec
Nobel Ilac Sanayii Ve Ticaret
Nishchay Pharmaceuticals
Natco Pharma
Jodas Expoim
Hetero Drugs
Globela Pharma
Glenmark Pharmaceuticals
Flagship Biotech International
Ethypharm
Dr Reddy's Laboratories
Cipla
Celon Laboratories
Cadila Pharmaceuticals
Accure Labs
Gefitinib Segment by Type
10 Tables/Box
30 Tables/Box
90 Tables/Box
Gefitinib Segment by Application
Drug Center
Hospital
Clinic
Others
Gefitinib Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gefitinib market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Gefitinib and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gefitinib.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Gefitinib manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Gefitinib by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Gefitinib in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 10 Tables/Box
- 30 Tables/Box
- 90 Tables/Box
Applications
- Drug Center
- Hospital
- Clinic
- Others
Companies covered
- Qilu Pharmaceutical
- AstraZeneca
- Zuventus Healthcare
- United Biotech
- Sichuan Xieli Pharmaceutical
- Panacea Biotec
- Nobel Ilac Sanayii Ve Ticaret
- Nishchay Pharmaceuticals
- Natco Pharma
- Jodas Expoim
- Hetero Drugs
- Globela Pharma
- Glenmark Pharmaceuticals
- Flagship Biotech International
- Ethypharm
- Dr Reddy's Laboratories
- Cipla
- Celon Laboratories
- Cadila Pharmaceuticals
- Accure Labs
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Gefitinib Market Size (2021-2032)
- 2.2.2 Global Gefitinib Sales (2021-2032)
- 2.2.3 Global Gefitinib Market Average Price (2021-2032)
- 2.3 Gefitinib by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 10 Tables/Box
- 2.3.3 30 Tables/Box
- 2.3.4 90 Tables/Box
- 2.4 Gefitinib by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Drug Center
- 2.4.3 Hospital
- 2.4.4 Clinic
- 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Gefitinib Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Gefitinib Sales (k pcs) of Manufacturers (2021-2026)
- 3.3 Global Gefitinib Revenue of Manufacturers (2021-2026)
- 3.4 Global Gefitinib Average Price by Manufacturers (2021-2026)
- 3.5 Global Gefitinib Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Gefitinib, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Gefitinib, Product Type & Application
- 3.8 Global Manufacturers of Gefitinib, Established Date
- 3.9 Global Gefitinib Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Qilu Pharmaceutical
- 4.1.1 Qilu Pharmaceutical Company Information
- 4.1.2 Qilu Pharmaceutical Business Overview
- 4.1.3 Qilu Pharmaceutical Gefitinib Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Qilu Pharmaceutical Gefitinib Product Portfolio
- 4.1.5 Qilu Pharmaceutical Recent Developments
- 4.2 AstraZeneca
- 4.2.1 AstraZeneca Company Information
- 4.2.2 AstraZeneca Business Overview
- 4.2.3 AstraZeneca Gefitinib Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 AstraZeneca Gefitinib Product Portfolio
- 4.2.5 AstraZeneca Recent Developments
- 4.3 Zuventus Healthcare
- 4.3.1 Zuventus Healthcare Company Information
- 4.3.2 Zuventus Healthcare Business Overview
- 4.3.3 Zuventus Healthcare Gefitinib Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Zuventus Healthcare Gefitinib Product Portfolio
- 4.3.5 Zuventus Healthcare Recent Developments
- 4.4 United Biotech
- 4.4.1 United Biotech Company Information
- 4.4.2 United Biotech Business Overview
- 4.4.3 United Biotech Gefitinib Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 United Biotech Gefitinib Product Portfolio
- 4.4.5 United Biotech Recent Developments
- 4.5 Sichuan Xieli Pharmaceutical
- 4.5.1 Sichuan Xieli Pharmaceutical Company Information
- 4.5.2 Sichuan Xieli Pharmaceutical Business Overview
- 4.5.3 Sichuan Xieli Pharmaceutical Gefitinib Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Sichuan Xieli Pharmaceutical Gefitinib Product Portfolio
- 4.5.5 Sichuan Xieli Pharmaceutical Recent Developments
- 4.6 Panacea Biotec
- 4.6.1 Panacea Biotec Company Information
- 4.6.2 Panacea Biotec Business Overview
- 4.6.3 Panacea Biotec Gefitinib Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Panacea Biotec Gefitinib Product Portfolio
- 4.6.5 Panacea Biotec Recent Developments
- 4.7 Nobel Ilac Sanayii Ve Ticaret
- 4.7.1 Nobel Ilac Sanayii Ve Ticaret Company Information
- 4.7.2 Nobel Ilac Sanayii Ve Ticaret Business Overview
- 4.7.3 Nobel Ilac Sanayii Ve Ticaret Gefitinib Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Nobel Ilac Sanayii Ve Ticaret Gefitinib Product Portfolio
- 4.7.5 Nobel Ilac Sanayii Ve Ticaret Recent Developments
- 4.8 Nishchay Pharmaceuticals
- 4.8.1 Nishchay Pharmaceuticals Company Information
- 4.8.2 Nishchay Pharmaceuticals Business Overview
- 4.8.3 Nishchay Pharmaceuticals Gefitinib Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Nishchay Pharmaceuticals Gefitinib Product Portfolio
- 4.8.5 Nishchay Pharmaceuticals Recent Developments
- 4.9 Natco Pharma
- 4.9.1 Natco Pharma Company Information
- 4.9.2 Natco Pharma Business Overview
- 4.9.3 Natco Pharma Gefitinib Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Natco Pharma Gefitinib Product Portfolio
- 4.9.5 Natco Pharma Recent Developments
- 4.10 Jodas Expoim
- 4.10.1 Jodas Expoim Company Information
- 4.10.2 Jodas Expoim Business Overview
- 4.10.3 Jodas Expoim Gefitinib Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Jodas Expoim Gefitinib Product Portfolio
- 4.10.5 Jodas Expoim Recent Developments
- 4.11 Hetero Drugs
- 4.11.1 Hetero Drugs Company Information
- 4.11.2 Hetero Drugs Business Overview
- 4.11.3 Hetero Drugs Gefitinib Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Hetero Drugs Gefitinib Product Portfolio
- 4.11.5 Hetero Drugs Recent Developments
- 4.12 Globela Pharma
- 4.12.1 Globela Pharma Company Information
- 4.12.2 Globela Pharma Business Overview
- 4.12.3 Globela Pharma Gefitinib Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Globela Pharma Gefitinib Product Portfolio
- 4.12.5 Globela Pharma Recent Developments
- 4.13 Glenmark Pharmaceuticals
- 4.13.1 Glenmark Pharmaceuticals Company Information
- 4.13.2 Glenmark Pharmaceuticals Business Overview
- 4.13.3 Glenmark Pharmaceuticals Gefitinib Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Glenmark Pharmaceuticals Gefitinib Product Portfolio
- 4.13.5 Glenmark Pharmaceuticals Recent Developments
- 4.14 Flagship Biotech International
- 4.14.1 Flagship Biotech International Company Information
- 4.14.2 Flagship Biotech International Business Overview
- 4.14.3 Flagship Biotech International Gefitinib Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Flagship Biotech International Gefitinib Product Portfolio
- 4.14.5 Flagship Biotech International Recent Developments
- 4.15 Ethypharm
- 4.15.1 Ethypharm Company Information
- 4.15.2 Ethypharm Business Overview
- 4.15.3 Ethypharm Gefitinib Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Ethypharm Gefitinib Product Portfolio
- 4.15.5 Ethypharm Recent Developments
- 4.16 Dr Reddy's Laboratories
- 4.16.1 Dr Reddy's Laboratories Company Information
- 4.16.2 Dr Reddy's Laboratories Business Overview
- 4.16.3 Dr Reddy's Laboratories Gefitinib Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Dr Reddy's Laboratories Gefitinib Product Portfolio
- 4.16.5 Dr Reddy's Laboratories Recent Developments
- 4.17 Cipla
- 4.17.1 Cipla Company Information
- 4.17.2 Cipla Business Overview
- 4.17.3 Cipla Gefitinib Sales, Revenue and Gross Margin (2021-2026)
- 4.17.4 Cipla Gefitinib Product Portfolio
- 4.17.5 Cipla Recent Developments
- 4.18 Celon Laboratories
- 4.18.1 Celon Laboratories Company Information
- 4.18.2 Celon Laboratories Business Overview
- 4.18.3 Celon Laboratories Gefitinib Sales, Revenue and Gross Margin (2021-2026)
- 4.18.4 Celon Laboratories Gefitinib Product Portfolio
- 4.18.5 Celon Laboratories Recent Developments
- 4.19 Cadila Pharmaceuticals
- 4.19.1 Cadila Pharmaceuticals Company Information
- 4.19.2 Cadila Pharmaceuticals Business Overview
- 4.19.3 Cadila Pharmaceuticals Gefitinib Sales, Revenue and Gross Margin (2021-2026)
- 4.19.4 Cadila Pharmaceuticals Gefitinib Product Portfolio
- 4.19.5 Cadila Pharmaceuticals Recent Developments
- 4.20 Accure Labs
- 4.20.1 Accure Labs Company Information
- 4.20.2 Accure Labs Business Overview
- 4.20.3 Accure Labs Gefitinib Sales, Revenue and Gross Margin (2021-2026)
- 4.20.4 Accure Labs Gefitinib Product Portfolio
- 4.20.5 Accure Labs Recent Developments
5 Global Gefitinib Market Scenario by Region
- 5.1 Global Gefitinib Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Gefitinib Sales by Region: 2021-2032
- 5.2.1 Global Gefitinib Sales by Region: 2021-2026
- 5.2.2 Global Gefitinib Sales by Region: 2027-2032
- 5.3 Global Gefitinib Revenue by Region: 2021-2032
- 5.3.1 Global Gefitinib Revenue by Region: 2021-2026
- 5.3.2 Global Gefitinib Revenue by Region: 2027-2032
- 5.4 North America Gefitinib Market Facts & Figures by Country
- 5.4.1 North America Gefitinib Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Gefitinib Sales by Country (2021-2032)
- 5.4.3 North America Gefitinib Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Gefitinib Market Facts & Figures by Country
- 5.5.1 Europe Gefitinib Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Gefitinib Sales by Country (2021-2032)
- 5.5.3 Europe Gefitinib Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Gefitinib Market Facts & Figures by Country
- 5.6.1 Asia Pacific Gefitinib Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Gefitinib Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Gefitinib Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Gefitinib Market Facts & Figures by Country
- 5.7.1 South America Gefitinib Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Gefitinib Sales by Country (2021-2032)
- 5.7.3 South America Gefitinib Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Gefitinib Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Gefitinib Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Gefitinib Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Gefitinib Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Gefitinib Sales by Type (2021-2032)
- 6.1.1 Global Gefitinib Sales by Type (2021-2032) & (k pcs)
- 6.1.2 Global Gefitinib Sales Market Share by Type (2021-2032)
- 6.2 Global Gefitinib Revenue by Type (2021-2032)
- 6.2.1 Global Gefitinib Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Gefitinib Revenue Market Share by Type (2021-2032)
- 6.3 Global Gefitinib Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Gefitinib Sales by Application (2021-2032)
- 7.1.1 Global Gefitinib Sales by Application (2021-2032) & (k pcs)
- 7.1.2 Global Gefitinib Sales Market Share by Application (2021-2032)
- 7.2 Global Gefitinib Revenue by Application (2021-2032)
- 7.2.1 Global Gefitinib Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Gefitinib Revenue Market Share by Application (2021-2032)
- 7.3 Global Gefitinib Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Gefitinib Value Chain Analysis
- 8.1.1 Gefitinib Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Gefitinib Production Mode & Process
- 8.2 Gefitinib Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Gefitinib Distributors
- 8.2.3 Gefitinib Customers
9 Global Gefitinib Analyzing Market Dynamics
- 9.1 Gefitinib Industry Trends
- 9.2 Gefitinib Industry Drivers
- 9.3 Gefitinib Industry Opportunities and Challenges
- 9.4 Gefitinib Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst